|
1
|
Bohlson SS, Silva R, Fonseca MI and Tenner
AJ: CD93 is rapidly shed from the surface of human myeloid cells
and the soluble form is detected in human plasma. J Immunol.
175:1239–1247. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Greenlee MC, Sullivan SA and Bohlson SS:
Detection and characterization of soluble CD93 released during
inflammation. Inflamm Res. 58:909–919. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jeon JW, Jung JG, Shin EC, Choi HI, Kim
HY, Cho ML, Kim SW, Jang YS, Sohn MH, Moon JH, et al: Soluble CD93
induces differentiation of monocytes and enhances TLR responses. J
Immunol. 185:4921–4927. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Park HJ, Han H, Lee SC, Son YW, Sim DW,
Park KH, Park YH, Jeong KY, Park JW and Lee JH: Soluble CD93 in
serum as a marker of allergic inflammation. Yonsei Med J.
58:598–603. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sigari N, Jalili A, Mahdawi L, Ghaderi E
and Shilan M: Soluble CD93 as a novel biomarker in asthma
exacerbation. Allergy Asthma Immunol Res. 8:461–465. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Duvetorp A, Slind Olsen R, Skarstedt M,
Söderman J and Seifert O: Psoriasis and pro-angiogenetic factor
CD93: Gene expression and association with gene polymorphism
suggests a role in disease pathogenesis. Acta Derm Venereol.
97:916–921. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Olsen RS, Lindh M, Vorkapic E, Andersson
RE, Zar N, Löfgren S, Dimberg J, Matussek A and Wågsäter D: CD93
gene polymorphism is associated with disseminated colorectal
cancer. Int J Colorectal Dis. 30:883–890. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Borah S, Vasudevan D and Swain RK: C-type
lectin family XIV members and angiogenesis. Oncol Lett.
18:3954–3962. 2019.PubMed/NCBI
|
|
9
|
Khan KA, McMurray JL, Mohammed F and
Bicknell R: C-type lectin domain group 14 proteins in vascular
biology, cancer and inflammation. FEBS J. 286:3299–3332. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
van der Ende MY, Hartman MH, Hagemeijer Y,
Meems LM, de Vries HS, Stolk RP, de Boer RA, Sijtsma A, van der
Meer P, Rienstra M and van der Harst P: The lifelines cohort study:
Prevalence and treatment of cardiovascular disease and risk
factors. Int J Cardiol. 228:495–500. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nanchen D, Klingenberg R, Gencer B, Räber
L, Carballo D, von Eckardstein A, Windecker S, Rodondi N, Lüscher
TF, Mach F, et al: Inflammation during acute coronary
syndromes-risk of cardiovascular events and bleeding. Int J
Cardiol. 287:13–18. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Golia E, Limongelli G, Natale F, Fimiani
F, Maddaloni V, Pariggiano I, Bianchi R, Crisci M, D'Acierno L,
Giordano R, et al: Inflammation and cardiovascular disease: From
pathogenesis to therapeutic target. Curr Atheroscler Rep.
16:4352014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ndrepepa G: Myeloperoxidase-A bridge
linking inflammation and oxidative stress with cardiovascular
disease. Clin Chim Acta. 493:36–51. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kaplan RC and Frishman WH: Systemic
inflammation as a cardiovascular disease risk factor and as a
potential target for drug therapy. Heart Dis. 3:326–332. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
van der Net JB, Oosterveer DM, Versmissen
J, Defesche JC, Yazdanpanah M, Aouizerat BE, Steyerberg EW, Malloy
MJ, Pullinger CR, Kastelein JJ, et al: Replication study of 10
genetic polymorphisms associated with coronary heart disease in a
specific high-risk population with familial hypercholesterolemia.
Eur Heart J. 29:2195–2201. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Youn JC, Yu HT, Jeon JW, Lee HS, Jang Y,
Park YW, Park YB, Shin EC and Ha JW: Soluble CD93 levels in
patients with acute myocardial infarction and its implication on
clinical outcome. PLoS One. 9:e965382014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mälarstig A, Silveira A, Wågsäter D,
Öhrvik J, Bäcklund A, Samnegård A, Khademi M, Hellenius ML, Leander
K, Olsson T, et al: Plasma CD93 concentration is a potential novel
biomarker for coronary artery disease. J Intern Med. 270:229–236.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Alehagen U, Ericsson A and Dahlström U:
Are there any significant differences between females and males in
the management of heart failure? Gender aspects of an elderly
population with symptoms associated with heart failure. J Card
Fail. 15:501–507. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Alehagen U and Wågsäter D: Gender
difference and genetic variance in lipoprotein receptor-related
protein 1 is associated with mortality. Biomed Rep. 1:1–5.
2019.PubMed/NCBI
|
|
20
|
Eriksson A, Stenlund H, Ahlm K, Boman K,
Bygren LO, Johansson LA, Olofsson BO, Wall S and Weinehall L:
Accuracy of death certificates of cardiovascular disease in a
community intervention in Sweden. Scand J Public Health.
41:883–889. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Greenlee MC, Sullivan SA and Bohlson SS:
CD93 and related family members: Their role in innate immunity.
Curr Drug Targets. 9:130–138. 2008. View Article : Google Scholar : PubMed/NCBI
|
